Press release
Chronic Hepatitis B Virus Pipeline Grows as 50+ Pharma Companies Advance Novel Hepatitis B Therapies, Finds DelveInsight | Ligand Pharmaceuticals, Dicerna Pharmaceuticals, Roche
Chronic Hepatitis B Virus Pipeline
Explore the latest breakthroughs in the Chronic Hepatitis B Virus treatment landscape. Learn more about the evolving HBV pipeline today @ https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Key Takeaways from the Chronic Hepatitis B Virus Pipeline Report
• In April 2026, TherVacB Phase I clinical data supported continued development for chronic hepatitis B patients who are at high risk of developing hepatocellular carcinoma (HCC).
• Pradefovir, a late-stage candidate from Ligand Pharmaceuticals, is an oral liver-targeting prodrug currently in Phase III development for chronic hepatitis B.
• RG6346, an RNAi therapeutic candidate developed by Dicerna Pharmaceuticals in collaboration with Roche, is currently in Phase II and aims to provide a functional cure by knocking down HBV genes.
• Chronic hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV), which can lead to serious outcomes like cirrhosis or liver cancer if not cleared.
• DelveInsight's HBV Pipeline Insight report depicts a robust clinical development space with 50+ active players advancing more than 55 pipeline therapies across multiple clinical stages.
• The leading Chronic Hepatitis B Virus companies include Ligand Pharmaceuticals, Dicerna Pharmaceuticals, Roche, and several other global pharmaceutical and biotech firms.
• Promising therapies in development include RNAi therapeutics, oral prodrugs, and undisclosed candidates segmented by early, mid, and late-stage clinical evaluation.
Download for updates and the latest revolution in HBV care @ https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Chronic Hepatitis B Virus Emerging Drugs Profile
• Pradefovir: Ligand Pharmaceuticals
Pradefovir is a notable late-stage pipeline candidate being developed by Ligand Pharmaceuticals for the treatment of chronic hepatitis B. It is designed as an oral liver-targeting prodrug, currently in Phase III clinical development. The drug aims to improve the treatment landscape for HBV patients by providing a targeted approach to address liver-specific infection complications.
• RG6346: Dicerna Pharmaceuticals / Roche
RG6346 is an innovative RNAi therapeutic candidate being developed through a collaboration between Dicerna Pharmaceuticals and Roche. Currently in Phase II clinical evaluation, RG6346 is designed to selectively knock down genes involved in the creation of HBV messenger RNA. This mechanism has the potential to provide a functional cure for patients suffering from chronic hepatitis B by suppressing viral replication at the genetic level.
For more information on the Chronic Hepatitis B Virus Emerging Drugs Profile, download DelveInsight's comprehensive Chronic Hepatitis B Virus Pipeline Insight report @ https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
The Chronic Hepatitis B Virus Pipeline Report Provides
• Detailed insights about companies developing therapies for Chronic Hepatitis B Virus, with aggregate therapies developed by each company.
• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for HBV treatment.
• HBV companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• HBV drugs under development based on stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the Chronic Hepatitis B Virus market.
Learn more about Chronic Hepatitis B Virus drug opportunities in our comprehensive HBV pipeline report @ https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Chronic Hepatitis B Virus Companies and Competitive Landscape
There are 50+ key companies, including Ligand Pharmaceuticals, Dicerna Pharmaceuticals, Roche, and others, developing therapies for Chronic Hepatitis B Virus, with over 55 pipeline drugs currently being tracked at various stages of clinical and non-clinical development globally.
DelveInsight's Chronic Hepatitis B Virus pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Chronic Hepatitis B Virus products have been categorized under various Molecule types such as:
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Discover the latest advancements in Chronic Hepatitis B Virus treatment by visiting our website. Stay informed @ https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Scope of the Chronic Hepatitis B Virus Pipeline Report
• Coverage: Global
• Chronic Hepatitis B Virus Companies: Ligand Pharmaceuticals, Dicerna Pharmaceuticals, Roche, and others.
• Chronic Hepatitis B Virus Therapies: Pradefovir, RG6346, and other pipeline candidates.
• Chronic Hepatitis B Virus Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination.
• Chronic Hepatitis B Virus Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III.
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Hepatitis B Virus Pipeline Grows as 50+ Pharma Companies Advance Novel Hepatitis B Therapies, Finds DelveInsight | Ligand Pharmaceuticals, Dicerna Pharmaceuticals, Roche here
News-ID: 4505232 • Views: …
More Releases from DelveInsight Business Research
Erectile Dysfunction Market Growth Outlook 2034: Epidemiology, Pipeline Therapie …
DelveInsight's "Erectile Dysfunction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Erectile Dysfunction, historical and forecasted epidemiology as well as the Erectile Dysfunction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Erectile Dysfunction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Erectile Dysfunction Market Forecast
https://www.delveinsight.com/sample-request/erectile-dysfunction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav
Some of the…
Degenerative Disc Disease Pipeline 2026: FDA Approvals and Clinical Trials Lands …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Degenerative Disc Disease pipeline constitutes 15+ key companies continuously working towards developing 15+ Degenerative Disc Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Degenerative Disc Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.…
Charcot Marie Tooth Disease Pipeline 2026: Therapies, MOA Insights, and Key Clin …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Charcot Marie Tooth Disease pipeline constitutes 13+ key companies continuously working towards developing 15+ Charcot Marie Tooth Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Charcot Marie Tooth Disease Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across…
Stargardt Disease Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Tria …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Stargardt Disease pipeline constitutes 20+ key companies continuously working towards developing 20+ Stargardt Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Stargardt Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
More Releases for Chronic
Chronic Pain Treatment Market - Relieving Chronic Pain: Discover the Latest Inno …
Newark, New Castle, USA: The "Chronic Pain Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Chronic Pain Treatment Market: https://www.growthplusreports.com/report/chronic-pain-treatment-market/8030
This latest report researches the industry structure,…
Refractory Chronic Cough Therapeutics Market - Silencing the Cough: Innovative T …
Newark, New Castle, USA: The "Refractory Chronic Cough Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Refractory Chronic Cough Therapeutics Market: https://www.growthplusreports.com/report/refractory-chronic-cough-therapeutics-market/7991
This latest report researches the…
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Chronic Phase Chronic Myeloid Leukemia Market to Witness Growth by 2032, Estimat …
DelveInsight's "Chronic Phase Chronic Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chronic Phase Chronic Myeloid Leukemia , historical and forecasted epidemiology as well as the Chronic Phase Chronic Myeloid Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Chronic Phase Chronic Myeloid Leukemia market report provides current treatment practices, emerging drugs, the market share…
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, T …
Orbisreserach.Com Adds “H1 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Market Pipeline Review 2017 Trend Analysis Report Report” To Its Research Database
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2017, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline landscape.
Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the…
Boot chronic pain
For immediate release
Due to our rushed lives and stressful environment, many people are suffering from chronic pain and fatigue.
We feel permanently tired and are barely able to get through our normal day. One is able to change this status when following the guidelines the book "Tired of being Tired to the point of being Gatvol (Fed Up). Some people will need a team of medical practitioners to help them…
